2
Dec
2016

21st Century Cures Rolls Thru House, Price Poised to Gut Obamacare, and Bluebird Soars

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Avidity Delivers, Foresite Raises $900M, & Lilly Alzheimer’s Drug Passes Scrutiny
AstraZeneca’s Big ASCO, Summit Breaks Out, & Structure’s Oral GLP-1 Advance
Merck Bets on the Eye, Merus Raises a Fortune, & Roche Leadership Change
Biogen Buys HI-Bio, Endeavor Reverses Lung Scarring, & Pfizer’s Latest Cuts